Can I Take St. John's Wort with Fosamax (Alendronate)?

What Is the Direct Drug Interaction Between St. John's Wort and Alendronate?

The direct pharmacokinetic interaction risk is low. Alendronate is not metabolized by the cytochrome P450 enzyme system, so St. John's Wort's well-documented induction of CYP3A4, CYP2C9, and P-glycoprotein does not affect alendronate's plasma levels or half-life in the way it affects drugs like cyclosporine, warfarin, or HIV protease inhibitors.

The FDA-approved prescribing information for alendronate confirms that the drug is excreted unchanged in urine and undergoes no hepatic biotransformation. [1] Because St. John's Wort's most clinically dangerous interactions run through CYP induction, this enzyme mismatch matters enormously.

How Alendronate Is Actually Absorbed and Eliminated

Alendronate has famously poor oral bioavailability: roughly 0.6 to 0.7% under strict fasting conditions. [1] It is absorbed in the upper gastrointestinal tract, distributed to bone, and cleared renally without modification. No CYP enzyme is involved at any step.

St. John's Wort's hypericin and hyperforin constituents are absorbed through the gut wall using some P-glycoprotein transporters. [2] Theoretically, high-dose St. John's Wort could alter intestinal P-gp activity, but alendronate's primary absorption mechanism is passive paracellular diffusion rather than P-gp-mediated transport, making this a theoretical rather than demonstrated concern.

Why St. John's Wort Causes So Many Other Drug Interactions

St. John's Wort earned its reputation as a high-risk supplement through documented interactions with drugs that depend on CYP3A4 clearance. A 2000 case series in The Lancet documented a 49% reduction in cyclosporine blood levels in organ-transplant patients who began taking St. John's Wort, leading to acute rejection episodes. [3] The FDA issued a public health advisory that same year. [4]

The NIH Office of Dietary Supplements notes that St. John's Wort can reduce plasma concentrations of indinavir by 57% and may similarly reduce levels of other CYP3A4-dependent drugs. [2] Alendronate simply does not belong to that pharmacological category.

Does St. John's Wort Affect Bone Health Independently?

This is where the clinical picture becomes more nuanced. St. John's Wort may have direct and indirect effects on bone metabolism that are worth knowing about when you are already taking a bone-protective medication like alendronate.

Preclinical Data on St. John's Wort and Bone

Animal research published in the journal Phytomedicine found that hyperforin, the primary active constituent of St. John's Wort, inhibited osteoclast activity in vitro. [5] If confirmed in human trials, this could theoretically produce an additive effect alongside alendronate's osteoclast-suppressing mechanism. No clinical trial in humans has tested this combination directly.

Serotonin Reuptake Inhibition and Fracture Risk

St. John's Wort inhibits serotonin, dopamine, and norepinephrine reuptake. [2] Prescription selective serotonin reuptake inhibitors (SSRIs) have been associated with reduced bone mineral density in observational data. A meta-analysis of 10 observational studies (N = 223,805) published in Osteoporosis International found that SSRI use was associated with a 1.7-fold increased risk of fracture compared with non-users. [6]

Whether St. John's Wort, as a mild serotonin reuptake inhibitor, carries the same bone risk is unknown. No randomized trial has measured DXA scores before and after St. John's Wort supplementation in a postmenopausal osteoporosis cohort. This is a genuine evidence gap. Patients taking alendronate for osteoporosis should mention St. John's Wort use to their physician so that DXA surveillance intervals can be adjusted if needed.

The Absorption Timing Problem: Where the Real Risk Lies

Even if a pharmacokinetic interaction is absent, the way alendronate must be taken creates a practical problem with any supplement, including St. John's Wort.

Alendronate's Strict Fasting Requirement

The FDA label states that alendronate must be taken with 6 to 8 ounces of plain water, at least 30 minutes (and ideally 60 minutes) before the first food, beverage, or other medication of the day. [1] Coffee, orange juice, mineral water, and calcium-containing supplements reduce alendronate bioavailability by more than 60% when taken within that window. [1]

St. John's Wort tablets or capsules taken at the same time as alendronate could mechanically compete for the same absorptive surface in the upper gut. This is not a drug-drug interaction in the pharmacokinetic sense. It is a drug-supplement timing problem that applies to essentially every oral supplement.

Recommended Timing Strategy

Take alendronate first thing in the morning with plain water, remain upright, and wait a full 60 minutes before taking St. John's Wort or any other supplement. Waiting the full 60 minutes (rather than the minimum 30) is advisable because some patients have slower gastric transit. This practical separation eliminates the absorption competition entirely.

The American Association of Clinical Endocrinology (AACE) 2020 postmenopausal osteoporosis clinical practice guideline emphasizes that "proper administration technique is a major determinant of bisphosphonate efficacy and gastrointestinal tolerability." [7]

St. John's Wort and GI Mucosal Effects

Alendronate is a known GI irritant. Esophageal irritation, esophagitis, and rare esophageal ulceration are recognized adverse effects, which is precisely why patients must stay upright for 30 to 60 minutes after each dose. [1]

St. John's Wort at standard doses (300 mg three times daily of 0.3% hypericin extract) is generally well-tolerated in the GI tract. [2] However, higher doses or non-standardized preparations have been associated with nausea and GI discomfort in clinical trials. The combination of two agents capable of GI mucosal irritation is worth monitoring, particularly in patients with a history of peptic ulcer disease or Barrett esophagus.

A 2005 Cochrane review of 37 randomized trials involving 4,925 patients found St. John's Wort was significantly more effective than placebo for mild-to-moderate depression and had a similar adverse-event profile to standard antidepressants. [8] GI complaints were listed as the most common side effect in 8 of the 37 trials reviewed. Patients already experiencing alendronate-related GI symptoms should disclose St. John's Wort use to their clinician.

What About Nutrient Interactions That Affect Bone?

Alendronate's efficacy depends heavily on adequate calcium and vitamin D status. The AACE guideline recommends 1,000 to 1,200 mg of elemental calcium daily and 800 to 1,000 IU of vitamin D3 for adults receiving bisphosphonate therapy. [7]

St. John's Wort does not directly deplete calcium or vitamin D. There is no published trial showing that St. John's Wort reduces serum 25-hydroxyvitamin D levels. By contrast, some herbal preparations sold alongside St. John's Wort (notably echinacea and valerian combination products) contain tannins that could reduce calcium absorption if taken within the alendronate timing window. Read supplement labels carefully and separate all supplements by at least 60 minutes from alendronate dosing.

Drug Interactions St. John's Wort Does Cause: A Clinical Context

To appreciate why the St. John's Wort-alendronate picture is reassuring, it helps to see what St. John's Wort actually does when it meets a CYP3A4-dependent drug.

The CYP3A4 Induction Mechanism

Hyperforin activates the pregnane X receptor (PXR), a nuclear receptor that upregulates transcription of CYP3A4, CYP2C9, CYP2C19, and the drug efflux transporter P-glycoprotein. [2] This induction can reduce plasma levels of affected drugs by 30 to 70% within 2 weeks of starting St. John's Wort, and the effect reverses within 2 weeks of stopping it.

Drugs That Are Genuinely Risky to Combine With St. John's Wort

Drugs where co-administration with St. John's Wort has produced clinically significant reductions in plasma levels include: cyclosporine (57% reduction documented in organ transplant recipients [3]), indinavir (57% reduction in AUC [2]), warfarin (reduced INR, increased clot risk), oral contraceptives (reduced contraceptive efficacy with documented breakthrough bleeding), digoxin (25% reduction in AUC reported in a crossover trial published in Clinical Pharmacology and Therapeutics [9]), and irinotecan (42% reduction in the active metabolite SN-38 [10]).

Alendronate does not belong on this list. It has no CYP footprint. The mechanism of concern simply does not apply.

When to Contact Your Prescriber

Even with a low direct interaction risk, certain clinical situations call for a conversation with your prescriber before combining St. John's Wort with alendronate.

Scenarios That Need Medical Review

You should contact your prescriber if:

• You have a history of esophageal disease, Barrett esophagus, or active peptic ulcer disease, because both agents could contribute to upper GI symptoms.
• You are also taking an SSRI or SNRI for depression. St. John's Wort plus an SSRI creates a real risk of serotonin syndrome, a potentially life-threatening drug-supplement interaction. [2]
• You are postmenopausal and your DXA T-score is below -2.5 (osteoporosis range), because any factor that could affect bone turnover deserves monitoring.
• You are taking any of the CYP3A4-dependent drugs listed above alongside alendronate. The risk is not between St. John's Wort and alendronate. The risk is between St. John's Wort and your other concurrent medications.
• Your alendronate dose is 70 mg weekly (the most common prescription dose for osteoporosis). Confirm with your pharmacist that no other supplement in your regimen falls within the 60-minute pre-dose window.

What "Disclosing Supplements" Actually Means in Practice

Many patients do not mention herbal supplements to their physicians because they assume "natural" means "safe and non-interacting." A 2017 survey published in JAMA Internal Medicine found that 34% of adults in the United States used complementary health products, and fewer than half disclosed this use to a clinician. [11] Alendronate's narrow absorption window and the broader drug interaction profile of St. John's Wort both make full disclosure genuinely useful, not just a formality.

Monitoring Parameters If You Take Both

If your clinician has reviewed the combination and cleared you to continue both, standard monitoring applies.

Bone mineral density by DXA should be measured at the lumbar spine and hip at baseline and every 1 to 2 years during bisphosphonate therapy, per the National Osteoporosis Foundation guidelines. [12] Serum calcium, phosphate, and 25-hydroxyvitamin D should be checked annually. Renal function (serum creatinine and estimated GFR) should be monitored because alendronate is renally cleared and is contraindicated when eGFR falls below 35 mL/min/1.73 m2. [1]

No additional monitoring specific to the St. John's Wort-alendronate combination is required by any current guideline, given the absence of a pharmacokinetic interaction. The monitoring schedule above is standard of care for bisphosphonate therapy regardless of St. John's Wort use.

Summary of the Interaction Classification

Interaction databases classify this combination differently depending on their methodology. The NIH Natural Medicines database rates St. John's Wort interactions primarily by CYP substrate status. [2] Because alendronate is not a CYP substrate, the combination falls into a "minor" or "no known interaction" classification in most clinical decision support tools.

The FDA drug label for alendronate lists calcium, antacids, and certain medications (such as aspirin and NSAIDs) as agents requiring timing consideration. [1] St. John's Wort is not listed as an interaction concern in the label.

This does not mean the combination has been formally studied in a randomized crossover pharmacokinetic trial. No such trial appears in the PubMed literature as of January 2025. The absence of documented interaction reflects the plausible pharmacology rather than completed human pharmacokinetic data for this specific pair.